--- canonical_name: Phellodendron amurense alternate_names: Amur Cork Tree, Amur Corktree, Huang Bai, Huangbai, Phellodendri Amurensis Cortex, Phellodendron amurense Rupr., Nexrutine canonical_topic: Phellodendron amurense for Health & Longevity short_topic_lc: phellodendron_amurense creation_date: 2026-0825-1800 creator_ai_fullname: Opus 5 ep_keywords: Traditional Chinese Medicine, Chinese Herbal Medicine, Berberine-Containing Herbs --- # Phellodendron amurense for Health & Longevity
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Amur Cork Tree, Amur Corktree, Huang Bai, Huangbai, Phellodendri Amurensis Cortex, Phellodendron amurense Rupr., Nexrutine ## Motivation *Phellodendron amurense*, the Amur cork tree, is a deciduous tree from northeastern Asia whose thick inner bark has been dried and used as a medicine for over a thousand years. The bark is rich in bitter yellow plant alkaloids — berberine chief among them — along with a family of citrus-like bitter compounds. Modern supplement makers sell it on its own and, more often, blended with magnolia bark or orange peel, marketing it for stress, joint comfort and weight control. Interest outside Asia grew in two waves. Nutrition companies built branded blends around the bark in the early 2000s and tested them in small trials on stressed, overweight adults. Separately, a university cancer group spent more than a decade studying a standardized bark extract in the laboratory and, eventually, in men with prostate cancer. The two lines of work rarely reference each other, and neither has produced a large trial. This review examines what the bark is, how its main compounds are thought to act, what human and laboratory studies report about its benefits and its harms, how it is dosed and sourced, and where the evidence is thin, contested, or drawn from products that contain other herbs alongside it. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews of *Phellodendron amurense* bark and its principal alkaloid, for orientation before the primary literature. * [Phellodendri Cortex: A Phytochemical, Pharmacological, and Pharmacokinetic Review](https://pubmed.ncbi.nlm.nih.gov/31057654/) - Sun et al., 2019 The most complete single map of the bark: 140 identified compounds, species-by-species differences between *P. amurense* and *P. chinense*, pharmacological actions, tissue distribution, and the berberine-related safety caveat. * [Protect Against Dopamine Deficit](https://www.lifeextension.com/magazine/2023/2/protect-against-dopamine-deficit) - Laurie Mathena Accessible account of why *Phellodendron* bark's inhibition of the dopamine-degrading enzyme MAO-B (monoamine oxidase B) interests the longevity field. Life Extension sells a *Phellodendron* product, so the framing is commercially interested. * [Should You Supplement With Berberine?](https://www.foundmyfitness.com/episodes/supplement-berberine-rhonda-patrick) - Rhonda Patrick Covers berberine — the protoberberine alkaloid *Phellodendron amurense* bark supplies — including its prescription-drug interactions, its effect on inflammatory markers and cholesterol, and how it compares with statins. * [Extracting the Benefit of Nexrutine® for Cancer Prevention](https://pubmed.ncbi.nlm.nih.gov/26539341/) - Hussain et al., 2015 Written by the group that ran the prostate programme, this narrative review lays out the multi-pathway rationale for a standardized bark extract and is candid about the gap between preclinical and clinical results. * [What is Berberine? A Summary of Berberine Alkaloid](https://lifespan.io/what-is-berberine-a-summary-of-berberine-alkaloid/) - Steve Hill Longevity-framed primer on berberine, the alkaloid *Phellodendron amurense* bark supplies, covering its energy-sensing pathway, its comparison with metformin and its documented drug interactions. **Search note:** No content naming *Phellodendron amurense* itself was found from Peter Attia, Andrew Huberman or Chris Kresser, on their own platforms or through general web search; each covers berberine only in passing inside broader supplement discussions, and Attia's berberine segment sits behind a subscriber-only feed. The Rhonda Patrick and Lifespan.io items above cover berberine, since the bark's systemic activity is attributed to that alkaloid. Five qualifying items were located, so the list is not padded with marginal material. ## Grokipedia * [Phellodendron amurense](https://grokipedia.com/page/Phellodendron_amurense) Grokipedia's dedicated article covers the tree's botany and range, its bark chemistry and berberine content, and its traditional use as Huang Bai, giving useful orientation before the primary literature. ## Examine * [Phellodendron amurense](https://examine.com/supplements/phellodendron-amurense/) Examine's entry summarizes the bark's traditional use for inflammation and bone pain, states plainly that Western research is sparse, and gives the commonly advocated 250–500 mg twice-daily dose. ## ConsumerLab No ConsumerLab article, product review or dedicated page exists for *Phellodendron amurense*. ConsumerLab has never tested a *Phellodendron* product; the herb appears on the site only as one ingredient inside a broader answer about stress supplements, which is not a dedicated page for this intervention. ## Systematic Reviews No systematic reviews or meta-analyses for *Phellodendron amurense* were found on PubMed as of August 20, 2026. Both sides of the trade-off are therefore unrepresented: neither the claimed stress, metabolic and joint benefits nor the principal risk — alkaloid-mediated interference with prescription drug levels — has a systematic review or meta-analysis specific to this bark. The pooled literature that does exist covers either isolated berberine or multi-herb Chinese formulas in which the bark is one of four or more components, and neither body can be attributed to *Phellodendron amurense* itself. ## Mechanism of Action *Phellodendron amurense* bark is a mixture, not a molecule. Roughly 84 constituents have been characterized in it, dominated by protoberberine alkaloids (berberine, palmatine, jatrorrhizine), the alkaloids magnoflorine and phellodendrine, bitter limonoids (obacunone, limonin, obaculactone) and phenolic acids such as chlorogenic acid ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)). The dominant proposed mechanism is suppression of inflammatory signalling. Berberine and palmatine inhibit NF-κB (nuclear factor kappa B, the master switch for inflammatory gene transcription) and downstream COX-2 (cyclooxygenase-2, the enzyme that generates pain and swelling signals), and dampen the MAPK relays ERK, JNK and p38 (mitogen-activated protein kinase, a signal chain that switches on cartilage-degrading enzymes) ([Kim et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21182922/)). Berberine also activates AMPK (the cell's energy sensor), the route through which its metabolic effects are usually explained. Magnoflorine and phellodendrine suppress the induction phase of cell-based immunity ([Mori et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7997475/)). A competing explanation holds that little of this happens systemically. Berberine's oral bioavailability is under one percent, because P-glycoprotein (a pump in the gut lining that expels foreign molecules) actively refuses it; blocking that pump raises absorption roughly sixfold ([Pan et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12530470/)). On this reading the bark acts mainly inside the gut and through bacteria-derived metabolites, with only trace parent alkaloid reaching tissue. What is absorbed is metabolized by liver CYP enzymes (cytochrome P450, the family that clears most drugs), notably CYP2D6, CYP1A2 and CYP3A4, and the bark's constituents distribute to plasma, liver, spleen, kidney and brain. ## Historical Context & Evolution The dried bark, called Huang Bai in Chinese and Ōbaku in Japanese, is one of the classical materia medica of East Asia, recorded for well over a millennium and grouped with the "heat-clearing, damp-drying" agents. Its original uses were infectious and inflammatory: dysentery, jaundice, urinary burning, vaginal discharge, mouth ulcers and suppurating skin sores. It was also a household commodity, dyeing cloth and paper yellow and forming the bitter core of the Japanese folk remedy Daranisuke, a stomach preparation attributed to the ascetic En no Gyōja. Western attention arrived by two unconnected routes. In the late 1990s and early 2000s a California nutraceutical company standardized the bark, paired it with magnolia bark for stress and with orange peel for joints, and ran the small placebo-controlled trials that still constitute most of the human evidence ([Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/)). Separately, from 2006 onward a laboratory at the University of Texas Health Science Center at San Antonio pursued a standardized bark extract as a prostate cancer preventive, publishing a decade of cell and transgenic-mouse work before a phase 2 trial in 21 men ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)). Neither line has been overturned; both simply stalled. The prostate trial closed early, and the supplement trials were never replicated at scale. The subsequent expansion of research on isolated berberine has largely absorbed the field's attention, leaving open the question — unresolved rather than settled — of whether the whole bark, with its limonoids and secondary alkaloids, behaves differently from the purified alkaloid. ## Expected Benefits Every human trial below tested a product sold by the company that funded the trial, and in every case the bark was combined with a second botanical. This financial interest is named again in the Conclusion. ### High 🟩 🟩 🟩 No benefit reaches this level. No adequately powered randomized controlled trial (a study in which participants are randomly assigned to treatment or to an inactive comparison treatment) of *Phellodendron amurense* bark on its own has been published. ### Medium 🟩 🟩 #### Reduced Cortisol Exposure and Perceived Stress ⚠️ Conflicted One of three placebo-controlled trials of a magnolia–*Phellodendron* bark blend reported significantly lower salivary cortisol and better mood in moderately stressed adults ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)); the other two found improved situational anxiety or a non-significant cortisol trend only ([Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/); [Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/)). All were short pilots of 26–56 completers, sponsored by the ingredient supplier, and tested a two-herb product, so the bark's independent contribution is unresolved. Chronic cortisol exposure — the outcome that matters for longevity — was not measured beyond six weeks. **Magnitude:** Salivary cortisol fell 18% against placebo over four weeks, with self-rated overall stress down 11%, fatigue down 31%, anger down 42% and vigour up 18%; the two earlier six-week trials found no significant cortisol change. ### Low 🟩 #### Knee Osteoarthritis Pain and Function An eight-week randomized trial of a *Phellodendron*–orange peel blend improved a validated knee pain-and-movement index and halved C-reactive protein, a blood marker of general inflammation ([Oben et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19682376/)). Human cartilage samples support the mechanism ([Kim et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21182922/)). Concurrent weight loss may explain part of the benefit. **Magnitude:** The Lequesne index fell from roughly 12 at baseline to 6.3 on treatment versus 11.8 on placebo in overweight participants at eight weeks; C-reactive protein dropped 49%. #### Modest Weight Loss and Prevention of Stress-Related Weight Gain Two industry-funded pilot trials found that bark blends blunted stress-related weight gain and produced modest loss in overweight adults ([Garrison & Chambliss, 2006](https://pubmed.ncbi.nlm.nih.gov/16454147/); [Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/)). Neither isolated the bark, both lost more than a third of participants, and neither followed anyone past eight weeks. **Magnitude:** The overweight treatment arm lost 4.2 kg (5.1% of body weight) in eight weeks versus 1.1 kg on placebo; in the six-week trial the placebo group gained 1.5 kg while the treated group did not change. #### Improved Lipids, Blood Pressure and Fasting Glucose The eight-week osteoarthritis trial also tracked cardiovascular markers and reported broad improvement in both weight strata ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/)). Because the same participants lost substantial weight, these marker changes cannot be separated from the weight change. Baseline values sat inside conventional reference ranges. **Magnitude:** In the overweight treatment arm at eight weeks, LDL cholesterol (the artery-damaging fraction) fell 44.6% from baseline versus 14.2% on placebo, HDL cholesterol (the protective fraction) rose 11.8%, triglycerides fell 18.1%, systolic pressure fell 6.0%, diastolic pressure 13.1%, and fasting glucose 19.6%. #### Prostate-Specific Antigen Decline in Prostate Cancer In an uncontrolled phase 2 study, 21 men took 500 mg of standardized bark extract three times daily for one to two months before surgery or radiotherapy ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)). Most showed a fall in prostate-specific antigen. With no comparison arm this is a tolerability signal, not efficacy. **Magnitude:** 81% of 21 men had a prostate-specific antigen decline by the end of the pre-treatment period; no comparison group existed and the trial was terminated early. #### Topical and Oral Antibacterial Activity A clinical letter describes a *Phellodendron amurense* facial mask applied to mild-to-moderate acne ([Zhang et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29808477/)), and laboratory work shows the extract eliminating the main tooth-decay bacterium without harming human skin cells ([Kim et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38794173/)). The traditional record for sores and mouth ulcers points the same way. **Magnitude:** Extract at 5 mg/mL completely inactivated *Streptococcus mutans* in culture, with growth inhibition rising across 1.25–5 mg/mL and no toxicity to human skin cells at those concentrations. ### Speculative 🟨 #### Selective MAO-B Inhibition and Dopamine Preservation Laboratory screens rank *Phellodendron amurense* bark among the most selective plant inhibitors of the dopamine-degrading enzyme MAO-B ([Zarmouh et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27341283/)). The basis is cell-free enzyme work; no human endpoint exists. #### Gout and Uric-Acid Inflammation Palmatine from the bark suppresses the NLRP3 inflammasome (a protein complex that triggers acute inflammatory attacks) in rodent gout models ([Jiang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39701220/)), matching the herb's classical use. The basis is mechanistic only. #### Longevity-Relevant Metabolic Signalling The AMPK activation attributed to the bark's berberine content is the pathway invoked for lifespan effects of energy-restriction mimetics. Nothing beyond mechanistic reasoning links this bark to any ageing endpoint in any species. #### Atopic Dermatitis and Inflammatory Skin Disease Bitter limonoids in the bark are proposed to drive an anti-eczema effect ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)); a topical two-herb preparation eased skin inflammation in mice ([Park et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26397864/)). Animal and mechanistic basis only. #### Gastroprotection and Ulcer Healing Alkaloids from the bark reduced experimental gastric ulcers in rats through nerve- and hormone-mediated routes ([Wang et al., 2017](https://pubmed.ncbi.nlm.nih.gov/27648555/)), matching the classical use for stomach complaints. The basis is rodent work only. #### Bone Preservation and Osteoporosis Protection Berberine and palmatine are named as bone-protective constituents of the genus ([Xin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38157118/)), and a bark-containing extract restored bone mass in rats ([Huh et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25230217/)). The basis is animal work only. #### Broad-Spectrum Antiviral Activity An aqueous bark extract inhibited several unrelated viruses in cell culture and in mice ([Kim et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27484768/)). The basis is laboratory and rodent work; no human antiviral endpoint has been tested. ## Benefit-Modifying Factors * **CYP2D6 and CYP3A4 variants:** These liver enzymes clear the absorbed alkaloids. Poor metabolizers hold higher plasma levels for longer and may respond to lower doses; ultrarapid metabolizers may see little systemic effect at conventional doses. * **Baseline cortisol and perceived stress:** The stress trials recruited people scoring above the population mean for anxiety and eating in response to stress. Adults with normal cortisol rhythms and low perceived stress have far less room to move. * **Baseline inflammatory markers:** The largest joint and inflammation responses occurred in participants who began with elevated C-reactive protein. Those already at low-inflammation levels showed smaller changes against their matched placebo groups. * **Baseline lipids and glucose:** In the cardiovascular pilot, participants started inside conventional reference ranges and the overweight stratum improved far more than the normal-weight stratum, indicating that benefit scales with baseline dysregulation. * **Adiposity:** Overweight participants outperformed normal-weight participants on weight, lipids, blood pressure, glucose and joint scores in the same trials, making body composition the single strongest published effect modifier. * **Sex-based differences:** Two of the three stress and weight trials enrolled only premenopausal women, so the female signal is better characterized. The mixed-sex trial reported no sex-stratified analysis, leaving male response inferred rather than measured. * **Pre-existing osteoarthritis:** Joint benefit was measured only in people with diagnosed knee osteoarthritis. Whether the same anti-inflammatory action does anything for asymptomatic joints has not been tested. * **Age:** All trials enrolled adults aged 20–65. Adults at the older end carry more concurrent medication and lower CYP3A4 reserve, which raises systemic exposure and may amplify both benefit and interaction risk. * **Gut microbiome composition:** Gut bacteria reduce berberine to a far better-absorbed form. Composition therefore determines how much alkaloid reaches the circulation, which is one plausible source of the inconsistent cortisol findings. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches this level. No trial of *Phellodendron amurense* has been large or long enough to establish any adverse effect with high-quality evidence; the strongest safety data come from studies of its principal alkaloid rather than of the bark. ### Medium 🟥 🟥 #### Raised Blood Levels of Interacting Prescription Drugs Berberine, the bark's dominant alkaloid, inhibits CYP3A4 and P-glycoprotein. In a randomized trial in kidney transplant recipients it substantially raised cyclosporine exposure ([Wu et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16133554/)). The bark delivers less berberine than the isolated alkaloid dose used there, so the size of the effect from a bark extract is unknown — but the direction is not in doubt, and it applies to statins, calcium-channel blockers, immunosuppressants and other narrow-margin drugs. **Magnitude:** 0.6 g of berberine daily raised cyclosporine trough concentration 88.3% and total exposure over the dosing interval 34.5%, cut apparent clearance 40.4%, and lengthened half-life by 2.7 hours. #### Gastrointestinal Intolerance Bitter protoberberine alkaloids commonly provoke nausea, cramping, constipation, diarrhoea and a persistent bitter taste, and the effect is dose-dependent. The bark trials reported no serious adverse events but did lose 35–44% of participants, dropouts variously citing lack of benefit ([Oben et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18492265/)). Because the alkaloids are barely absorbed, the gut sees the highest concentration of anything in the body, which is the proposed mechanism. **Magnitude:** Direction and conditions only: intolerance rises with dose and on an empty stomach, and falls when the dose is split and taken with meals; no bark trial published a per-symptom incidence rate, so the literature reports no outcome figure. #### Unsuitability Around Pregnancy, Nursing and the Newborn Period Berberine crosses the placenta and displaces bilirubin from albumin, the mechanism behind the classical warning against berberine-bearing herbs in newborns and around birth ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)). Jaundiced newborns and people with haemolytic conditions (in which red blood cells break down early) are the identified susceptible groups. Severity is potentially serious and the exposure is entirely avoidable. **Magnitude:** Not quantified in available studies. No controlled trial has measured bilirubin displacement or newborn outcomes after maternal *Phellodendron* use; the signal rests on the alkaloid's albumin-binding chemistry and paediatric case observations. ### Low 🟥 #### Suppression of Cell-Based Immunity Magnoflorine and phellodendrine, both present in the bark, suppressed two standard tests of cell-based immunity in mice when given during the induction phase ([Mori et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7997475/)). Where the bark is used continuously for longevity, blunted cell-based immunity is a plausible and under-examined cost. **Magnitude:** Both alkaloids suppressed the responses at 5–20 mg/kg given by injection for 5–8 consecutive days in mice; no equivalent human immune endpoint has been measured. #### Renal Tubular Change at High Doses A 28-day rodent study found no toxicity at 250 or 500 mg/kg, but mild kidney tubular degeneration at 750 mg/kg ([Alam et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34386623/)). Human doses sit far below that ceiling on a body-weight basis, so it marks a boundary rather than a live hazard. **Magnitude:** Mild tubular degeneration at 750 mg/kg daily for 28 days in rats; the single-dose lethal level exceeded 2000 mg/kg, and no blood-count or tissue abnormality appeared at 500 mg/kg. #### Electrolyte and Urinary Adverse Events at Therapeutic Doses The only trial to dose the bark alone at 1500 mg daily recorded two transient grade 3 events — low potassium and urinary incontinence — among 21 men, with no grade 4 events ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)). All were older men with prostate cancer, several also on radiotherapy, which confounds attribution. **Magnitude:** 2 of 21 participants (9.5%) had a transient grade 3 event — moderately severe on the standard five-point adverse-event scale — during the bark-only phase; none occurred once radiotherapy was added. #### Additive Sedation from Combination Products Most retail *Phellodendron* is sold with magnolia bark, whose honokiol and magnolol act on the brain's main calming receptor. Daytime drowsiness reported with these blends is attributable to the magnolia component, not the bark ([Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/)). **Magnitude:** Direction and conditions only: sedation tracks the magnolia dose and evening timing rather than the *Phellodendron* dose; the published trials recorded no sedation incidence, so the literature reports no outcome figure. ### Speculative 🟨 #### Additive Blood-Glucose Lowering Fasting glucose fell almost 20% in one [trial arm](https://pubmed.ncbi.nlm.nih.gov/18492265/). Stacked with metformin, sulfonylureas or insulin, the same action could in principle push glucose too low. No hypoglycaemic event has been reported with this bark. #### Additive Blood-Pressure Lowering Systolic pressure fell 6% and diastolic 13% in one [trial arm](https://pubmed.ncbi.nlm.nih.gov/18492265/), confounded by concurrent weight loss. Stacked with antihypertensives, the same action could in principle cause dizziness or fainting. No such event has been reported. #### Idiosyncratic Liver Injury Berberine itself has not been linked to clinically apparent liver injury in the [LiverTox monograph](https://pubmed.ncbi.nlm.nih.gov/33242239/), but multi-herb products containing *Phellodendron* have appeared in isolated injury reports. The basis is case-level and confounded by co-ingredients. #### Interference with Prostate Cancer Screening If the prostate-specific antigen decline seen in the [phase 2 study](https://pubmed.ncbi.nlm.nih.gov/25205619/) is real and not tumour-related, routine use could mask a rising screening value. This is inference; no screening-accuracy study exists. ## Risk-Modifying Factors * **G6PD deficiency:** Glucose-6-phosphate dehydrogenase (the enzyme that protects red blood cells from oxidative rupture) is deficient in these individuals, the named susceptible group for berberine-related red-cell breakdown and bilirubin displacement. * **CYP2D6 and CYP3A5 variants:** These enzymes clear both the bark's alkaloids and many co-prescribed drugs. Poor-metabolizer genotypes compound the interaction risk, since substrate and inhibitor accumulate together. * **Baseline bilirubin and liver enzymes:** Raised bilirubin marks reduced albumin-binding reserve and therefore greater vulnerability to displacement; raised liver enzymes signal a liver less able to clear the absorbed alkaloid fraction. * **Baseline potassium and kidney function:** Low-normal potassium and reduced filtration widen the consequence of the electrolyte disturbance observed in the prostate trial and of the tubular change seen in rodents. * **Sex-based differences:** Women have modestly lower first-pass clearance through CYP3A4 and were the sole participants in two trials, so their tolerability data are better characterized; male tolerability rests on 21 prostate patients. * **Pre-existing conditions:** Transplant immunosuppression, autoimmune disease, symptomatic slow heart rate, low blood pressure, cholestatic liver disease (impaired bile flow) and haemolytic anaemia each convert a theoretical interaction into a clinically consequential one. * **Age:** Adults past 65 carry more concurrent medication, lower kidney clearance and reduced CYP3A4 reserve, so the same dose produces higher exposure and a wider interaction surface than in younger adults. ## Key Interactions & Contraindications * **Calcineurin inhibitors (cyclosporine, tacrolimus) — absolute caution:** Berberine raises cyclosporine trough levels by roughly 88%, risking kidney toxicity. Mitigation: complete avoidance, or drug-level measurement before starting and again at one and four weeks. * **CYP3A4-substrate statins (simvastatin, atorvastatin, lovastatin) — monitor:** Raised statin exposure increases muscle-injury risk, including rhabdomyolysis (severe muscle breakdown that releases protein damaging the kidneys). Mitigation: a non-CYP3A4 statin such as rosuvastatin, or separation of use. * **CYP2D6-substrate cardiac drugs (metoprolol, propafenone, flecainide) — monitor:** Higher plasma levels can cause bradycardia (slow heart rate) or irregular rhythm. Mitigation: weekly heart-rate and blood-pressure checks for the first month, with prescription dose reduction where indicated. * **Antihypertensives (amlodipine, lisinopril, losartan) — monitor:** The bark's own blood-pressure lowering adds to the prescription effect, risking dizziness or fainting on standing. Mitigation: home blood-pressure logging for two weeks after starting, with prescription review if readings fall below 110 mmHg systolic. * **Anticoagulants and antiplatelets (warfarin, clopidogrel, apixaban) — caution:** Alkaloid-driven CYP2C9 and CYP3A4 inhibition can raise anticoagulant exposure and bleeding risk. Mitigation: weekly international normalised ratio (a clotting-time measure) for four weeks after starting. * **Glucose-lowering drugs (metformin, glipizide, insulin) — monitor:** The additive glucose-lowering effect risks hypoglycaemia (blood sugar falling too low). Mitigation: increased home glucose testing for two weeks, and a downward step in the prescription dose beforehand. * **Immunosuppressant and biologic therapy (methotrexate, tumour necrosis factor inhibitors) — caution:** The bark's alkaloids suppress cell-based immunity in animals, plausibly compounding therapeutic immunosuppression. Mitigation: avoidance during active immunosuppressive treatment. * **Over-the-counter P-glycoprotein substrates (loperamide, dextromethorphan, diphenhydramine) — monitor:** Pump inhibition raises absorption and, for loperamide, central and cardiac exposure. Mitigation: four-hour dose separation, and avoidance of high-dose loperamide entirely. * **Over-the-counter acid suppressants and antacids (omeprazole, calcium carbonate) — caution:** Raising stomach pH reduces alkaloid solubility and absorption, blunting the effect. Mitigation: a two-hour gap between the bark and any antacid or proton-pump inhibitor. * **Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) — monitor:** Both suppress COX-2, so joint benefit is duplicated rather than added, while gastric irritation compounds. Mitigation: one agent or the other rather than stacking through a flare. * **Other berberine-bearing supplements (goldenseal, Oregon grape, *Coptis chinensis*, isolated berberine) — caution:** Stacking multiplies total alkaloid load and every interaction above without adding a distinct mechanism. Mitigation: a total berberine tally across products, and a single source. * **Sedative supplements (magnolia bark, valerian, melatonin, kava) — monitor:** Most retail *Phellodendron* already contains magnolia, so further sedatives risk daytime drowsiness. Mitigation: label inspection for magnolia content before combining, and evening-only timing for any stack. * **Glucose-lowering supplements (bitter melon, cinnamon, chromium, alpha-lipoic acid) — monitor:** These add to the bark's own glucose-lowering action, the additive-effect case most likely to matter in practice. Mitigation: one agent introduced at a time, with fasting glucose retested after two weeks. * **Alcohol and other liver-cleared intake — caution:** Competition for CYP-mediated clearance raises exposure to both. Mitigation: avoidance of heavy drinking during use, particularly alongside any narrow-margin prescription drug. **Populations who should avoid Phellodendron amurense:** * Pregnancy at any stage, and lactation * Newborns and infants under 1 year, and any jaundiced infant * Solid-organ transplant recipients on calcineurin inhibitors * Documented G6PD deficiency or other haemolytic anaemia * Child-Pugh Class B or C liver impairment (moderate to severe liver scarring), and cholestatic liver disease * Chronic kidney disease with a kidney filtration rate (eGFR) below 30 mL/min/1.73 m² * Symptomatic bradycardia below 50 beats per minute, or systolic blood pressure below 100 mmHg * Scheduled surgery within 14 days, because of the bleeding and glucose interactions * Active autoimmune disease under immunosuppressive treatment ## Risk Mitigation Strategies * **Medication reconciliation before the first dose:** Listing every prescription against the CYP3A4, CYP2D6 and P-glycoprotein interactions above is the single step that prevents the highest-consequence risk, raised levels of narrow-margin drugs. * **Low starting dose with slow titration:** Beginning at 250 mg once daily for one week, then 250 mg twice daily, then the target dose over three weeks limits the gastrointestinal intolerance that drives most discontinuation. * **Consistent dosing with meals:** Taking the extract mid-meal buffers the bitter alkaloids against the stomach lining, reducing nausea and cramping; it also matches the dosing used in every published trial. * **Two-hour separation from acid suppressants:** Spacing the dose away from antacids and proton-pump inhibitors preserves alkaloid solubility, preventing the silent loss of effect that leads to unnecessary dose escalation. * **Four-week safety bloods:** Repeating liver enzymes, bilirubin and potassium at four weeks catches the liver-enzyme, bilirubin-displacement and electrolyte signals seen in the prostate and rodent studies before they become symptomatic. * **Drug-level checks for interacting prescriptions:** Measuring cyclosporine, tacrolimus or clotting time at baseline, one week and four weeks converts an unpredictable interaction into a managed one with a documented trajectory. * **Total berberine tally across products:** Tallying berberine from goldenseal, Oregon grape, *Coptis* and isolated berberine alongside the bark prevents unintentional alkaloid stacking, which multiplies interaction and gastrointestinal risk. * **Fourteen-day washout before surgery:** A two-week washout clears the bleeding and glucose-lowering interactions ahead of any procedure, avoiding intraoperative bleeding and unstable glucose around the operation. * **Label check for magnolia content:** Confirming whether a product is bark-only or a magnolia blend before combining it with any sedative prevents the additive daytime drowsiness attributable to the second herb. ## Therapeutic Protocol * **Standard bark-only dose:** 250–500 mg of standardized bark extract twice daily with meals is the range advocated for the single herb, giving 500–1000 mg daily; Examine.com reports this as the commonly used dose. * **Research dose for prostate intent:** 500 mg three times daily of the standardized extract, the regimen used for one to two months in the only trial of the bark on its own ([Swanson et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25205619/)). * **Stress and weight-management blend:** 250 mg of a magnolia–*Phellodendron* blend three times daily, or 500 mg twice daily, matching the trials that reported cortisol and mood effects. * **Joint-support blend:** Two 370 mg capsules of a *Phellodendron*–orange peel blend twice daily, the regimen used in the knee osteoarthritis and cardiovascular pilots. * **Competing approaches — decoction, standardized extract, isolated alkaloid:** East Asian practice uses a whole-bark decoction within a multi-herb formula; Western practice uses a standardized extract; a third camp bypasses the plant for isolated berberine. None is established as superior. * **Who developed each approach:** Next Pharmaceuticals of Salinas, California standardized and popularized both the magnolia and orange-peel blends; the prostate protocol came from the Kumar and Ghosh laboratories at the University of Texas Health Science Center. * **Best time of day:** Split doses with breakfast, lunch and dinner in the trial protocols. Stress and sleep endpoints favour weighting the evening dose; dopamine-preservation intent argues for the morning, though no trial has compared timings. * **Half-life and dosing frequency:** Berberine's plasma half-life runs to a few hours, while its liver metabolites persist far longer. Three-times-daily dosing in the trials reflects the parent compound's short residence rather than any tested comparison. * **Single versus split dosing:** No head-to-head comparison exists. Every published trial used two or three divided doses, which also limits the gastrointestinal load per dose given how little alkaloid is absorbed. * **Genetic polymorphisms:** CYP2D6 and CYP3A5 genotype shifts systemic alkaloid exposure and may justify the lower end of the range. Confirmed G6PD deficiency removes the intervention from consideration entirely rather than adjusting its dose. * **Sex-based differences:** No trial has compared male and female dosing. Two of three stress and weight trials enrolled only premenopausal women at 750 mg daily of the blend, so female tolerability at that dose is best documented. * **Age-related considerations:** Adults past 65 typically start at the bottom of the range because of reduced CYP3A4 reserve and more concurrent medication; no trial enrolled participants above 80, so protocols for that group are extrapolated. * **Baseline biomarkers as a dose input:** Elevated C-reactive protein, elevated fasting glucose and raised body mass index all predicted larger responses, so those starting with normal markers have little published rationale for exceeding the low end. * **Pre-existing conditions:** Diagnosed knee osteoarthritis, stress-driven eating and overweight define the populations in which any effect was actually demonstrated; outside those, the protocol rests on mechanism rather than on measured response. ## Discontinuation & Cycling * **Not a lifelong protocol:** Every trial ran four to eight weeks. Nothing in the literature supports continuous multi-year use, and the animal immune-suppression signal argues against assuming indefinite use is neutral. * **No withdrawal syndrome documented:** No trial has reported rebound anxiety, cortisol overshoot or discontinuation symptoms. The alkaloids do not act on dependence-forming receptors, and abrupt cessation has produced no recorded harm. * **Tapering is not required pharmacologically:** Because there is no withdrawal signal, stopping outright is the norm. Where the bark accompanied an interacting drug, that drug's level shifts on stopping and needs rechecking. * **Cycling is undocumented but commonly practised:** Eight to twelve weeks on followed by four weeks off mirrors the trial durations. No study has tested whether tolerance develops or whether cycling preserves any effect. * **Interaction unwind on stopping:** Ending the bark removes CYP3A4 inhibition, so levels of cyclosporine, statins and anticoagulants fall. Prescription doses adjusted upward during use need review within two weeks of stopping. ## Sourcing and Quality * **Species verification:** Two species are sold as Huang Bai. *Phellodendron amurense* and *Phellodendron chinense* differ measurably in constituent profile, and *P. chinense* is typically the higher-alkaloid bark, so a label naming only the genus is uninformative. * **Standardization to berberine:** Reputable extracts state a berberine percentage. Without it, a capsule's alkaloid content can vary several-fold between harvests, growing regions and bark age, making both dose and interaction risk unpredictable. * **Third-party testing:** Certification by an independent laboratory such as USP, NSF or Informed Choice covers identity, alkaloid content, heavy metals and microbial contamination. Bark grown in industrial regions can accumulate cadmium and lead. * **Bark, not leaf or fruit:** The medicinal part is the dried trunk bark. Leaf extracts are cheaper, are chemically different, and are sometimes substituted; product literature naming the plant part is a basic quality signal. * **Named branded extracts:** Nexrutine, from Next Pharmaceuticals, is the standardized bark extract used in the prostate research; Relora is the magnolia blend used in the stress and weight trials. Both are sold through multiple retail brands. * **Adulteration with cheap berberine:** Because berberine hydrochloride is inexpensive, spiking a weak bark extract with isolated alkaloid raises assay values without supplying the limonoids or secondary alkaloids that distinguish the whole bark. ## Practical Considerations * **Time to effect:** Mood and stress changes appeared at four weeks in the trials; joint, lipid, glucose and weight changes were measured at four and eight weeks. Nothing meaningful was recorded before two weeks of continuous use. * **Pitfall — assuming the trial results apply to the bark alone:** Nearly all human evidence comes from two-herb products. Buying single-herb *Phellodendron* and expecting the published cortisol or joint results is the commonest error. * **Pitfall — ignoring the interaction surface:** The bark is bought as a gentle botanical and taken alongside statins or anticoagulants without a second thought, which is precisely where its highest-consequence risk sits. * **Pitfall — dosing on an empty stomach:** Every trial dosed with meals. Fasted dosing raises nausea and bitterness sharply and is the usual reason people abandon the supplement within two weeks. * **Regulatory status:** In the United States the bark is a dietary supplement under the Dietary Supplement Health and Education Act, unapproved by the Food and Drug Administration for any disease. In China, Japan and Korea it is a pharmacopoeial herbal drug. * **Cost and accessibility:** Inexpensive and widely available online, typically well under a dollar a day. Neither cost nor supply is a limiting factor, so no access-related barrier applies to this intervention. * **Reimbursement asymmetry:** Insurers and national health systems reimburse generic anti-inflammatory and lipid-lowering drugs but not supplements, so no institutional payer has a financial reason to fund trials of this bark — a structural reason the evidence base stays commercial and small. ## Interaction with Foundational Habits * **Sleep:** Indirect and generally favourable in blends. Lower evening cortisol plausibly eases sleep onset, but the measured sleep benefit came from magnolia's honokiol, not the bark. Bark-only products are not sedating; the one trial measuring sleep quality and latency found no change ([Kalman et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18426577/)). Evening dosing carries no penalty. * **Nutrition:** Direct and dose-relevant. Every trial dosed with meals, which buffers gastric irritation; fat in the meal does not appear to matter, since the alkaloids are poorly absorbed regardless. Antacids and proton-pump inhibitors blunt absorption by raising stomach pH. Gut bacteria convert berberine into a better-absorbed form, so fibre intake plausibly modulates exposure. * **Exercise:** Indirect, with a caution. Lower cortisol exposure plausibly supports recovery from training, and the stress trial ([Talbott et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23924268/)) proposed athletes as a target group without testing them. No evidence suggests blunted hypertrophy. Because the bark suppresses inflammatory signalling, it could dull the adaptive inflammatory response to resistance training, like anti-inflammatory drugs. * **Stress management:** Direct and potentiating. This is the domain with the best human data: cortisol output and self-rated stress both fell against placebo in stressed adults. The effect was measured on top of participants' ordinary lives, not against structured stress-reduction practice, so whether it adds to meditation, breathwork or sleep extension is untested. ## Monitoring Protocol & Defining Success Baseline testing precedes the first dose in published protocols, because *Phellodendron amurense* acts on the same liver enzymes and inflammatory pathways these markers track. The baseline panel used in practice covers liver enzymes and bilirubin, a complete blood count, a metabolic panel including potassium and kidney filtration, fasting glucose and glycated haemoglobin, a standard lipid panel, and high-sensitivity C-reactive protein. Men over 45 using the bark with prostate intent add prostate-specific antigen. Where a narrow-margin prescription drug is in use — a transplant immunosuppressant above all — a drug level is drawn before starting. Ongoing monitoring follows a simple cadence: liver enzymes and potassium repeat at four weeks, the full panel at three months, then every six months. Levels for interacting prescriptions repeat at one and four weeks after any dose change. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Alanine aminotransferase | 10–26 U/L (men), 8–22 U/L (women) | Detects liver stress from alkaloid load or from a co-administered drug | Abbreviated ALT; conventional labs flag only above 40–55 U/L; no fasting needed; paired with aspartate aminotransferase (AST) | | Total and direct bilirubin | Total 0.3–1.0 mg/dL; direct below 0.3 mg/dL | Tracks the albumin-displacement mechanism behind the newborn warning | Rises with fasting and with Gilbert syndrome, a harmless inherited variant; drawn non-fasting for a stable reading | | Potassium | 4.0–4.5 mmol/L | The transient severe event in the only bark-only trial was low potassium | Conventional range extends down to 3.5 mmol/L; damaged samples read falsely high, so outliers are redrawn | | Estimated glomerular filtration rate | Above 90 mL/min/1.73 m² | Rodent kidney tubular change at high doses makes filtration the relevant safety margin | Abbreviated eGFR; a cystatin C-based estimate is preferable in muscular individuals; no heavy exercise for 48 hours before | | High-sensitivity C-reactive protein | Below 0.5 mg/L | The inflammation marker that moved most in the joint trial; the main efficacy readout | Abbreviated hs-CRP; conventional cut-off is 3.0 mg/L; invalid within two weeks of any infection or injury | | Fasting glucose and glycated haemoglobin | Glucose 75–86 mg/dL; glycated haemoglobin 4.8–5.2% | Captures the glucose-lowering effect and any additive low-blood-sugar risk | Glycated haemoglobin is abbreviated HbA1c; needs a 10–12 hour fast; reads falsely low when red cells break down early | | Lipid panel | LDL below 100 mg/dL; HDL above 55 mg/dL; triglycerides below 80 mg/dL | The cardiovascular readout that improved most in the eight-week pilot | LDL is low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol; 12-hour fast; morning draw; paired with apolipoprotein B | | Morning salivary cortisol | 0.10–0.35 µg/dL at waking | The primary endpoint of the stress trials and the clearest efficacy signal | Collected within 30 minutes of waking, before food, caffeine or brushing teeth; a four-point daily curve reads better than one sample | | Prostate-specific antigen | Below 2.5 ng/mL, or stable against personal baseline | Relevant only where prostate intent applies; the bark may lower the reading | Abbreviated PSA; no ejaculation or cycling for 48 hours before; the reading may fall without any tumour change | | Cyclosporine or tacrolimus trough level | No established target for this purpose; tracked against the individual's own pre-supplement trough | Direct measurement of the highest-consequence interaction | Drawn immediately before the next dose; repeated at one and four weeks after starting or stopping the bark | Qualitative markers tracked alongside the laboratory panel in practice: * Perceived stress and irritability, rated daily on a simple 0–10 scale * Sleep onset latency and number of night wakings * Morning energy and afternoon slump, which the mood trials captured as vigour and fatigue * Joint stiffness on rising and stair-climbing comfort, where joint intent applies * Digestive tolerance: nausea, bitterness, stool frequency and consistency * Appetite and stress-driven eating episodes per week ## Emerging Research * **Bark extract in prostate cancer:** The phase 2 study of a standardized extract ([NCT01705652](https://clinicaltrials.gov/study/NCT01705652), 21 participants, primary endpoint prostate-specific antigen) was terminated early. Its published tolerability data remain the only human trial of the bark alone, and no successor trial has been registered. * **Blend under acute induced stress:** A completed 36-participant study of the magnolia–*Phellodendron* blend ([NCT02734251](https://clinicaltrials.gov/study/NCT02734251)) used state-anxiety score after an induced stressor as its primary endpoint. Sponsored by the ingredient supplier; results have not appeared in the peer-reviewed literature. * **Phellodendron-containing formula for diabetic wounds:** A multicentre randomized trial of Mailuo Shutong Pills, in which *Phellodendron* bark is a named component ([NCT07258381](https://clinicaltrials.gov/study/NCT07258381), 56 participants, wound-area reduction at 14 days), was registered for a December 2025 start. * **Topical bark preparation in herpes zoster:** A completed phase 4 trial combined fire-needle therapy with a *Phellodendron* bark compress in acute herpes zoster, or shingles ([NCT06985589](https://clinicaltrials.gov/study/NCT06985589), 32 participants), testing the classical topical use against a symptom-and-sign score. * **Post-surgical wound healing:** A 60-participant trial of a compound *Phellodendron* decoction after anal fistulotomy ([NCT06663527](https://clinicaltrials.gov/study/NCT06663527)) completed in early 2025, with healing time as its primary endpoint — the traditional wound-and-sore indication tested formally. * **Species standardization could strengthen or weaken the case:** *P. amurense* and *P. chinense* differ substantially in constituent profile ([Sun et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31057654/)). Trials that fail to specify species may be measuring different medicines, which would explain some inconsistency and could invalidate pooled conclusions. * **Absorption enhancement could change the risk-benefit balance:** Because P-glycoprotein blockade raises berberine absorption around sixfold ([Pan et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12530470/)), enhanced-delivery formulations would amplify systemic effects — and every drug interaction — beyond anything the existing trials measured. * **The immune-suppression signal needs human work:** Magnoflorine and phellodendrine suppressed cell-based immunity in mice ([Mori et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7997475/)). A human immune-function study could substantially weaken the case for continuous longevity-oriented use, and none is registered. * **MAO-B inhibition awaits a human endpoint:** The bark ranks among the most selective plant inhibitors of the dopamine-degrading enzyme in cell-free screens ([Mazzio et al., 2013](https://pubmed.ncbi.nlm.nih.gov/22887993/)). Whether that survives one-percent oral bioavailability is the question that would strengthen or collapse the neuroprotection claim. ## Conclusion *Phellodendron amurense* is a bark used for centuries in East Asian medicine and sold today mainly as a bitter yellow extract, usually blended with magnolia bark or orange peel rather than given alone. Its bitter alkaloids and citrus-like compounds calm inflammatory signalling in cell and animal work, yet those same alkaloids barely enter the bloodstream when swallowed, so much of what the bark does may happen in the gut rather than throughout the body. The human record is small and awkward to interpret. The strongest signal is a lowering of stress hormone output and an improvement in self-reported mood in people under everyday strain; the trials showing it are short, small, funded by the companies selling the blend, and built on products containing a second herb, so the bark's own contribution cannot be separated. Weaker signals point to easier knee movement, modest weight loss, and friendlier blood fat and blood sugar readings. Laboratory work on the prostate and on the brain's dopamine-clearing enzyme is striking but unmatched by controlled human results. Against that sit the practical hazards of a berberine-bearing bark: it raises blood levels of some prescription medicines, upsets some stomachs, damps down cell-based immune responses in animals, and is unsuitable around pregnancy and the newborn period. Almost everything published on benefit comes from parties selling the material, which leaves the evidence base thin, commercially shaped and unresolved. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**